Chase Investment Counsel’s GSK GSK Stock Holding History

Chase Investment Counsel’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-20,000	Closed	-$725K	–	128
2023 Q3	$725K	Buy	+20,000	New	+$710K	0.36%	70

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chase Investment Counsel's GSK Position: Q4 2023 in Review

Chase Investment Counsel sold out of GSK (GSK) in Q4 2023, closing a stake of 20,000 shares — an estimated $725K sold.

Chase Investment Counsel first reported a position in GSK in Q3 2023 and held it in 1 quarter. The position peaked at $725K in Q3 2023. 895 funds tracked by Wall St. Rank hold GSK as of Q4 2023.

Chase Investment Counsel reported no remaining GSK position as of Q4 2023 after selling out during the quarter.
Chase Investment Counsel sold 20,000 GSK shares in Q4 2023, an estimated $725K.
Chase Investment Counsel first reported a position in GSK in Q3 2023 and held it in 1 quarter.
Chase Investment Counsel's GSK position peaked at $725K in Q3 2023.
895 funds tracked by Wall St. Rank held GSK as of Q4 2023.

Based on Chase Investment Counsel's 13F filing for Q4 2023, filed 5 Feb 2024.